Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

SARS-CoV-2 Nucleocapsid Antikörper

SARS-CoV-2 N Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, IF Wirt: Maus Monoclonal 3851 unconjugated
Produktnummer ABIN6952432
  • Target Alle SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) Antikörper anzeigen
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Reaktivität
    • 80
    • 13
    • 5
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2)
    Wirt
    • 34
    • 26
    • 21
    • 4
    • 1
    • 1
    Maus
    Klonalität
    • 68
    • 13
    • 5
    Monoklonal
    Konjugat
    • 67
    • 11
    • 5
    • 2
    • 1
    Dieser SARS-CoV-2 Nucleocapsid Antikörper ist unkonjugiert
    Applikation
    • 71
    • 35
    • 10
    • 10
    • 6
    • 5
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Western Blotting (WB), Immunofluorescence (IF)
    Spezifität
    Specific for the nucleoprotein of the SARS virus.
    Aufreinigung
    SARS-CoV-2 (COVID-19, 2019-nCoV) Nucleoprotein antibody is purified from ascites fluid or culture medium by protein A chromoatography or sequential differential precipitations.
    Klon
    3851
    Isotyp
    IgG2b
    Top Product
    Discover our top product SARS-CoV-2 N Primärantikörper
  • Applikationshinweise
    Optimal working dilution should be determined by the investigator.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    phosphate saline buffer (0.01M, pH 7.2) containing 0.1 % sodium azide preservative. No stabilizing proteins have been added.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    antibody can be stored at -20°C, stable for one year.
    Haltbarkeit
    12 months
  • Qiao, Wotring, Zhang, Jiang, Xiao, Watt, Gattis, Scandalis, Freier, Zheng, Pretto, Ellison, Swayze, Guo, Sexton, Chinnaiyan: "Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection." in: PloS one, Vol. 18, Issue 2, pp. e0281281, (2023) (PubMed).

    Qiao, Wotring, Zheng, Zhang, Zhang, Jiang, Pretto, Eyunni, Parolia, He, Cheng, Cao, Wang, Su, Ellison, Wang, Qin, Yan, Zhou, Ma, Sexton, Chinnaiyan: "Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Issue 30, pp. e2221809120, (2023) (PubMed).

    Wotring, Fursmidt, Ward, Sexton: "Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern." in: Journal of dairy science, (2022) (PubMed).

    Sherman, Mirabelli, Tang, Khan, Leix, Kennedy, Graham, Willer, Tai, Sexton, Wobus, Emmer: "Identification of cell type specific ACE2 modifiers by CRISPR screening." in: PLoS pathogens, Vol. 18, Issue 3, pp. e1010377, (2022) (PubMed).

    Mirabelli, Sherman, Wotring, El Saghir, Bragazzi Cunha, Harder, Sexton, Emmer, Wobus: "ARF6 is an important host factor for SARS-CoV-2 infection in vitro." in: bioRxiv : the preprint server for biology, (2022) (PubMed).

    Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: bioRxiv : the preprint server for biology, (2022) (PubMed).

    Yao, Subedi, Liu, Khalasawi, Pretto-Kernahan, Wotring, Wang, Yin, Jiang, Fu, Dimitrion, Li, Veenstra, Yi, McKinnon, McKinnon, Sexton, Zhou, Mi: "Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes." in: Cell discovery, Vol. 8, Issue 1, pp. 89, (2022) (PubMed).

    Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: Vaccines, Vol. 10, Issue 8, (2022) (PubMed).

    Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Pretto, Qiao, Zhang, Frum, Kadambi, Amin, OMeara, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Chinnaiyan, Sexton: "Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Issue 36, (2021) (PubMed).

    Baang, Smith, Mirabelli, Valesano, Manthei, Bachman, Wobus, Adams, Washer, Martin, Lauring: "Prolonged SARS-CoV-2 replication in an immunocompromised patient." in: The Journal of infectious diseases, (2020) (PubMed).

    Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Frum, Kadambi, Amin, OMeara, Pretto, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Sexton: "Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19." in: bioRxiv : the preprint server for biology, (2020) (PubMed).

  • Target
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Andere Bezeichnung
    SARS-CoV-2 Nucleocapsid Protein (SARS-CoV-2 N Produkte)
    Synonyme
    nucleocapsid phosphoprotein antikoerper, N antikoerper
    Substanzklasse
    Viral Protein
Sie sind hier:
Kundenservice